HEIGHT AND MORTALITY AFTER MYOCARDIAL INFARCTION

A case-control analysis was conducted to determine the relationship between height and mortality among patients enrolled in the already completed Beta Blocker Heart Attack Trial (BHAT). In a basic model including height (continuous) and relevant covariates the relative risk (RR) per 4-inch reduction...

Full description

Saved in:
Bibliographic Details
Published in:Journal of community health 1995-08, Vol.20 (4), p.335-343
Main Authors: Rosenberg, Carl R., Shore, Roy E., Pasternack, Bernard S.
Format: Article
Language:English
Subjects:
Adult
Aged
Attrition (Research Studies)
Body Height - physiology
Cardiovascular diseases
Case-Control Studies
Cause of Death
Clinical trials
College Students
Confidence Intervals
Double-Blind Method
Electrocardiography, Ambulatory - drug effects
Female
Females
Gender Differences
Heart attacks
Heart Disorders
Height
Humans
Individual Characteristics
Male
Males
Maximum Likelihood Statistics
Middle Aged
Mortality
Myocardial infarction
Myocardial Infarction - drug therapy
Myocardial Infarction - mortality
Patients
Predictor Variables
Propranolol - therapeutic use
Regression (Statistics)
Statistical Analysis
Statistical Significance
Survival Analysis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A case-control analysis was conducted to determine the relationship between height and mortality among patients enrolled in the already completed Beta Blocker Heart Attack Trial (BHAT). In a basic model including height (continuous) and relevant covariates the relative risk (RR) per 4-inch reduction in height (approximately 1 standard deviation) was 1.18 (95% confidence interval, 0.92 to 1.51). When sex was considered, the effect of short stature on mortality was found to be restricted to male subjects. The male RR per 4-inch reduction in height was 1.26 (0.96 to 1.63) whereas for women it was 0.89 (0.49 to 1.59). In males not randomized to propranolol (untreated) the effect was further modified with a RR per 4-inch reduction in height of 1.41 (1.00 to 1.99). It is hypothesized that short stature could be a marker for factors operating as far back as childhood that predispose males to mortality from coronary heart disease in later life.
ISSN:0094-5145
1573-3610
DOI:10.1007/BF02283058